Nabriva Therapeutics PLC
Change company Symbol lookup
Select an option...
NBRV Nabriva Therapeutics PLC
HRB H & R Block Inc
GM General Motors Co
NDAQ Nasdaq Inc
DYYXF DB Commodity Double Long ETN
KIQ Kelso Technologies Inc
MMM 3M Co
CBOE Cboe Global Markets Inc
PFE Pfizer Inc
DOW Dow Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Pharmaceuticals | Small Cap Growth
Based in Ireland
Company profile

Nabriva Therapeutics plc is a biopharmaceutical company engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company’s product XENLETA (lefamulin), is a semi-synthetic pleuromutilin antibiotic for systematic administration in humans. It inhibits the synthesis of bacterial protein, which is required for bacteria to grow by binding with high affinity, high specificity and at molecular targets that are different than other antibiotic classes. The Company is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

Price
Delayed
$0.6231
Day's Change
-0.0385 (-5.82%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.6599
Day's Low
0.6001
Volume
(Heavy Day)

Today's volume of 1,800,352 shares is on pace to be much greater than NBRV's 10-day average volume of 2,903,555 shares.

1,800,352

Wendy's misses earnings expectations but shares jump

7:27 am ET May 6, 2020 (MarketWatch)
Print

Wendy's Co. (WEN) reported first-quarter net income of $14.4 million, or 6 cents per share, down from $31.9 million, or 14 cents per share, last year. Adjusted EPS of 9 cents missed the FactSet consensus for 10 cents. Revenue of $405.0 million was down from $408.6 million last year and below the $414.0 million FactSet outlook. U.S. same-store sales were flat while global same-store sales fell 0.2%. The FactSet consensus was for domestic same-store sales growth of 2.9% and overall same-store sales growth of 2.9%. Wendy's had a cash balance of $365 million as of May 3 after full drawing down its variable funding senior secured notes revolving financing facility, reducing its second-quarter dividend and taking other measures due to the coronavirus. Nearly all (96%) of Wendy's restaurants are operating, including 99% in the U.S., with drive-thru and delivery only. Wendy's has said that disruptions to the beef supply chain (http://www.marketwatch.com/story/wendys-says-some-menu-items-will-have-limited-availability-due-to-beef-supply-disruptions-2020-05-05) has put limits on the availability of certain menu items. Wendy's stock jumped nearly 6% in Wednesday premarket trading and is up 1.2% for the past year. The S&P 500 index is down 2.2% for the last 12 months.

-Tonya Garcia; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

May 06, 2020 07:27 ET (11:27 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.